Profile data is unavailable for this security.
About the company
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. Its product categories include HIV, COVID-19, Viral Hepatitis, Oncology and others. Under HIV, it offers Biktarvy, Genvoya, Descovy, Odefsey, Complera /Eviplera, Truvada, Stribild and Sunlenca. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of COVID-19. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / Chronic hepatitis delta virus (Vemlidy and Viread). Under oncology, it offers cell therapy containing Tecartus and Yescarta. Its other products include AmBisome and Letairis. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients.
- Revenue in USD (TTM)27.12bn
- Net income in USD5.66bn
- Incorporated1987
- Employees18.00k
- LocationGilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
- Phone+1 (650) 574-3000
- Fax+1 (650) 578-9264
- Websitehttps://www.gilead.com/
Mergers & acquisitions
Acquired company | GILD:NSQ since announced | Transaction value |
---|---|---|
XinThera Inc | -6.78% | -- |